Kronos Bio, Inc. (NASDAQ:KRON – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q3 2023 earnings per share (EPS) estimates for Kronos Bio in a note issued to investors on Thursday, January 12th. Jefferies Financial Group analyst M. Yee forecasts that the company will post earnings of ($0.47) per share for the quarter. The consensus estimate for Kronos Bio’s current full-year earnings is ($2.48) per share. Jefferies Financial Group also issued estimates for Kronos Bio’s Q4 2023 earnings at ($0.49) EPS.
Kronos Bio (NASDAQ:KRON – Get Rating) last released its earnings results on Tuesday, November 8th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.07.
Kronos Bio Stock Performance
NASDAQ KRON opened at $2.62 on Monday. The company has a market capitalization of $149.07 million, a PE ratio of -0.89 and a beta of 1.08. The business’s fifty day moving average is $1.93 and its 200 day moving average is $3.31. Kronos Bio has a fifty-two week low of $1.35 and a fifty-two week high of $10.94.
Institutional Investors Weigh In On Kronos Bio
Large investors have recently made changes to their positions in the company. Delphia USA Inc. bought a new stake in shares of Kronos Bio in the second quarter worth about $52,000. Privium Fund Management UK Ltd bought a new stake in shares of Kronos Bio in the second quarter worth about $1,566,000. Amalgamated Bank purchased a new position in Kronos Bio in the first quarter worth about $35,000. The Manufacturers Life Insurance Company purchased a new position in Kronos Bio in the third quarter worth about $48,000. Finally, Federated Hermes Inc. purchased a new position in Kronos Bio in the second quarter worth about $1,039,000. 63.39% of the stock is owned by institutional investors.
Insider Buying and Selling at Kronos Bio
In other news, VP Jorge Dimartino sold 18,657 shares of Kronos Bio stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $1.81, for a total value of $33,769.17. Following the sale, the vice president now directly owns 219,478 shares of the company’s stock, valued at $397,255.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 28.20% of the company’s stock.
Kronos Bio Company Profile
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
- Get a free copy of the StockNews.com research report on Kronos Bio (KRON)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.